Investment Rating - The investment rating for the company is "Buy" (maintained) [3] Core Views - The company's performance in 2025 met expectations, and there is anticipation for a recovery in 2026 [3] - The company achieved total revenue of 5.52 billion RMB in 2025, a slight decrease of 0.37% year-on-year, with a net profit of 1.91 billion RMB, down 7.15% year-on-year [6] - The company is focusing on product iteration and expanding its product matrix, particularly in the medical beauty sector, which is expected to drive long-term growth [6] - The company has established a strong market position in the medical device sector and is expanding its product offerings to include various skincare solutions [6] Financial Summary - Revenue projections for 2026 are estimated at 6.07 billion RMB, with a year-on-year growth rate of 9.9% [4] - The projected net profit for 2026 is 1.98 billion RMB, reflecting a growth of 3.4% year-on-year [4] - The company's gross margin is expected to remain strong at approximately 79.3% in 2026 [7] - The company maintains a low debt-to-equity ratio of 8.45%, indicating strong financial health [6]

Core Viewpoint - The Chinese cosmetics industry is projected to reach a market size of 1.1 trillion yuan, with domestic brands surpassing international brands in market share and consumer preference significantly increasing for domestic products [1][2]. Group 1: High-Quality Development and New Productive Forces - The domestic cosmetics market retail sales are expected to reach 470 billion yuan by 2025, indicating that the industry has entered a trillion-yuan market phase, with domestic brands holding a substantial market share [2][4]. - New productive forces are essential for high-quality development, transitioning the industry from traditional manufacturing to intelligent and lean production, enhancing efficiency and product consistency through automation and smart technologies [4][5]. Group 2: Intelligent Manufacturing Practices of Domestic Brands - Over the past decade, the cosmetics manufacturing industry has evolved from experience-driven to data-driven, with a clear three-stage evolution path: semi-automated, automated production lines, and now towards data-driven intelligent stages [6][8]. - Leading brands like Han Shu and Hua Xi have made significant investments in intelligent manufacturing, achieving production capacity increases and quality control improvements, with Han Shu's AI-driven production line capable of producing 2 million bottles daily [8][10]. Group 3: R&D Innovation and Cost Management - R&D expenditure rates vary by category, with skincare products averaging 1.5%-3%, while medical beauty products range from 2%-5%, indicating a differentiated investment strategy based on product type [19][20]. - Domestic brands like Shangmei and Perleya have R&D personnel ratios comparable to international brands, showcasing their commitment to innovation and development [21][22]. Group 4: International Competitiveness of Domestic Brands - Domestic brands such as Han Shu, Perleya, and Bei Tai Ni have made significant advancements in product quality, R&D innovation, and supply chain integration, enhancing their competitiveness in the global market [28][30]. - The establishment of AI-driven unmanned workshops and 5G smart factories by domestic brands demonstrates their technological capabilities and operational efficiency, positioning them among the world's best in the cosmetics industry [30].

Investment Rating - The report maintains a "Buy" rating for the company [1] Core Insights - The company reported its 2025 annual results, which met expectations, with revenue of 55.19 billion RMB, a slight decrease of 0.4% year-on-year, and a net profit of 19.15 billion RMB, down 7.1% year-on-year [6] - The medical beauty business is contributing a new growth curve, with the core product line and multiple series matrix continuously improving [6] - The company is focusing on shareholder returns, with a total dividend payout of approximately 1.29 billion RMB for the 2025 fiscal year [6] Financial Data and Profit Forecast - Revenue projections for 2026 are estimated at 60.45 billion RMB, with a year-on-year growth rate of 10% [5] - The net profit attributable to ordinary shareholders is forecasted to be 19.17 billion RMB in 2026, with a growth rate of 0% [5] - The earnings per share (EPS) for 2026 is projected to be 1.79 RMB, with a price-to-earnings (PE) ratio of 14.6 [5] Business Performance - The company's main product, "可复美," generated revenue of 44.7 billion RMB, accounting for 81% of total revenue, despite external shocks and industry competition [6] - The direct sales channel remained stable, with direct revenue of 41.4 billion RMB, representing 74.9% of total revenue [6] - The company is positioned in the collagen protein market, with both "可复美" and "可丽金" brands maintaining high growth rates [6]

Industry and Company Analysis - The lithium battery industry is experiencing accelerated industrialization, with companies like Samsung SDI and Chasing releasing AI-specific all-solid-state batteries, and plans for mass production by 2027 [3][33] - CATL maintains high-speed growth in performance, indicating strong market demand and operational efficiency [3][33] - The European natural gas futures prices are rising, which may impact energy costs for battery production and overall industry dynamics [3][33] Financial Performance Insights - BOSS Zhipin reported a revenue growth rate exceeding expectations for Q4 2025, indicating a positive trend in spring recruitment [3][33] -卓越教育集团 emphasizes high dividends and shareholder returns, suggesting a competitive advantage in the Greater Bay Area [3][33] - Huazhu Group's operational turning point is validated, with expansion in market share and cyclical recovery [3][33] - Tencent is actively investing in AI, focusing on enhancing model capabilities, which may drive future growth [3][33] - Zhongan Online's diversified layout has deepened, leading to significant profit improvements [3][33] - Dongfang Caifu's performance is on an upward trend, seeking new growth spaces [3][33] - Nanjing Steel's main business profitability remains stable, although its coking business has negatively impacted overall performance [3][33] - Guokang Gold Group is progressing with the expansion of its mining capacity, indicating strong future growth potential [3][33] - Juzhi Biotechnology's short-term adjustments do not alter its long-term growth logic, with a promising pipeline in the medical beauty sector [3][33]

Investment Rating - The report maintains a BUY rating for Giant Biogene, expecting earnings pressure to ease progressively through 2026E and injectables to drive medium- to long-term growth [1][8]. Core Views - Giant Biogene reported revenue of RMB5,519 million in 2025, a slight decline of 0.4% YoY, and an attributable net profit of RMB1,915 million, down 7.2% YoY, which was in line with expectations given external headwinds and competition [1][2]. - The gross margin decreased by 1.8 percentage points YoY to 80.3%, primarily due to changes in product mix [1]. - For 2026E, sales growth is expected to recover gradually, driven by stronger brand promotion for KOMFYMED and Collgene, an expanded product portfolio, and the commercialization of newly approved Class III injectables [1][8]. - The target price has been lowered to HK$38.70 from HK$53.89, reflecting a revised revenue and net profit CAGR forecast from 18%/17% to 11%/8% for 2025-28E due to intensified competition [1][3]. Financial Summary - Revenue projections for FY26E, FY27E, and FY28E are RMB6,073 million, RMB6,809 million, and RMB7,522 million respectively, with YoY growth rates of 10.1%, 12.1%, and 10.5% [2][12]. - Attributable net profit is expected to be RMB1,964 million in FY26E, RMB2,201 million in FY27E, and RMB2,432 million in FY28E, with corresponding YoY growth rates of 2.6%, 12.1%, and 10.5% [2][12]. - The P/E ratio is projected to be 14.7x for FY26E, 13.1x for FY27E, and 11.9x for FY28E [2][12]. Product and Market Insights - KOMFYMED's revenue was RMB4,470 million in 2025, down 1.6% YoY, while Collgene grew by 9.2% YoY to RMB918 million [1][8]. - The company plans to launch several key products in 2026E, including KOMFYMED Focus Cream 2.0 and new additions to the Focus and Regular series, to support recovery [1][8]. - Offline direct sales increased by 32% YoY to RMB225 million in 2025, contributing 4.1% to total revenue, driven by the expansion of KOMFYMED offline stores [1][8]. Regulatory and Commercialization Developments - Giant Biogene received NMPA approvals for two Class III injectables in late 2025 and early 2026, with commercialization expected to begin in 2Q26E [1][8]. - The company is preparing for commercialization through market research and distributor selection, leveraging its nationwide sales network [1][8].

Investment Rating - The report maintains an "Outperform" rating for Giant Biogene with a target price of HKD 36.20, implying a potential upside of 17.9% from the current price of HKD 30.70 [2][3]. Core Insights - The company’s 2025 results were broadly in line with expectations, with total revenue of RMB 5.52 billion, a slight decline of 0.4% year-on-year. The attributable net profit was RMB 1.91 billion, down 7.1% year-on-year, but exceeded estimates by 2.1% [4][15]. - Revenue for 2026 is projected to grow to RMB 6.06 billion, representing a year-on-year increase of 9.8%, with net profit expected to reach RMB 2.00 billion, reflecting a growth of 4.6% [3][14]. - The company is focusing on the commercialization of its medical aesthetics business, with two Class III medical device products approved and set to launch in 2026. This is expected to create a dual-growth engine alongside its skincare products [6][17]. Financial Performance - For 2025, the gross margin was 80.3%, down 1.8 percentage points year-on-year, while the net profit margin was 34.7% [4][15]. - The company’s revenue breakdown shows functional skincare products generated RMB 4.34 billion, a 0.8% increase year-on-year, while medical dressings fell to RMB 1.16 billion, a decline of 4.8% [4][15]. - The report highlights a healthy balance sheet with cash and cash equivalents of RMB 6.31 billion as of the end of 2025, and no interest-bearing debt [19]. Product Performance - The KomfyMed brand saw a slight revenue decline of 1.6% to RMB 4.47 billion, while the Collgene brand achieved a 9.2% increase to RMB 0.92 billion, driven by online channel expansion [5][16]. - The management has set clear targets for new product launches in 2026, including the Focus Series essence and Zhixu Series, with expectations for significant sales growth [8][18]. Market Outlook - The report anticipates that the company will return to growth in 2026, with a focus on new product performance and the medical aesthetics business as key drivers [3][14]. - The competitive landscape is noted to be intensifying, which may impact profit growth, leading to a revised P/E multiple of 17x for 2026 [3][14].

Investment Rating - The report maintains an "Outperform" rating for Giant Biogene with a target price of HKD 36.20, implying a potential upside of 17.9% from the current price of HKD 30.70 [2][3]. Core Insights - The company’s 2025 results were broadly in line with expectations, with total revenue of RMB 5.52 billion, a slight decline of 0.4% year-on-year. The attributable net profit was RMB 1.91 billion, down 7.1% year-on-year, but exceeded estimates by 2.1% [4][15]. - Revenue for 2026 is projected to grow to RMB 6.06 billion, representing a year-on-year increase of 9.8%, with attributable net profit expected to reach RMB 2.00 billion, reflecting a growth of 4.6% [3][14]. - The gross profit margin is expected to decline slightly from 80.3% in 2025 to 79.7% in 2026, while the net profit margin is projected to be 33.1% [10][14]. Financial Performance - The company achieved a gross margin of 80.3% in 2025, which was slightly below expectations, while the selling expense ratio was better than anticipated at 37.3% [4][15]. - Functional skincare products generated revenue of RMB 4.34 billion, growing 0.8% year-on-year, outperforming forecasts by 8.7%. In contrast, medical dressings saw a decline of 4.8% year-on-year to RMB 1.16 billion, falling short of projections by 21.6% [4][15][16]. Future Focus Areas - Key focus area 1 is the commercialization timeline and sales ramp-up of the medical aesthetics business, with two Class III medical device products approved and expected to launch in 2026. The company aims to leverage its network of approximately 4,700 hospitals and clinics [6][17]. - Key focus area 2 involves the sales performance of new products in 2026, particularly the Focus Series essence and the Zhixu Series. Management anticipates significant growth from these new launches, with specific sales targets set for the first year [8][18]. Balance Sheet and Dividends - As of the end of 2025, the company reported cash and cash equivalents of RMB 6.31 billion, a 56.5% increase year-on-year, with no interest-bearing debt. The total dividends declared for 2025 were RMB 1.29 billion, representing a payout ratio of approximately 67% [19].

Investment Rating - The industry investment rating is "Positive" (maintained) [1] Core Viewpoints - The report highlights the release of 16 measures by the Ministry of Commerce to promote travel-related consumption, focusing on expanding inbound tourism and enhancing service offerings [4] - The report notes the implementation of spring and autumn breaks in various regions, which is expected to stimulate travel and consumption [4] - The performance of companies such as China Duty Free Group and Giant Bio is discussed, with China Duty Free reporting a revenue of 53.694 billion yuan in 2025, a year-on-year decline of 4.92% [4][5] - The report emphasizes the growth of emerging consumer goods, reflecting new consumption concepts among younger generations [15] Summary by Relevant Sections Industry Performance - The new consumption sector saw a decline in stock performance, with the beauty care index down 4.78% and the retail index down 4.55% during the week of March 16 to March 20, 2026 [8] Key Industry Data - Retail sales in the textile and apparel category increased by 10.4% year-on-year for January-February [9] - Retail sales in the cosmetics category rose by 4.5% year-on-year for January-February [9] - Retail sales in the gold and silver jewelry category increased by 13.0% year-on-year for January-February [17] Company Performance - China Duty Free Group's fourth-quarter revenue for 2025 was 13.831 billion yuan, showing a year-on-year growth of 2.81% [4] - Giant Bio reported a revenue of approximately 5.52 billion yuan for 2025, remaining stable year-on-year [5] - Wanchen Group achieved a revenue of 51.46 billion yuan in 2025, a year-on-year increase of 59.2% [5] Investment Analysis Recommendations - The report suggests focusing on high-quality domestic brands in the beauty sector, such as Mao Geping and Shangmei [15] - In the gold and jewelry sector, it recommends brands favored by younger consumers, such as Laopu Gold and Chaohongji [15] - For the trendy toy sector, companies with strong IP creation and operation experience, like Pop Mart, are highlighted [15]

Investment Rating - The investment rating for the company is "Buy" (maintained) [4][12]. Core Views - The company reported a revenue of 55.19 billion yuan for 2025, a slight decrease of 0.4% year-on-year, and a net profit of 19.15 billion yuan, down 7.2% year-on-year [5][6]. - The decline in performance is attributed to short-term product structure changes, logistics upgrades, and the commissioning of a new factory, but the company maintains strong core technology barriers and brand advantages [6][9]. - The medical beauty business is expected to become a growth engine for the company, with significant potential for future expansion [6][9]. Financial Performance Summary - Revenue and Profit Forecast: - 2024A: Revenue of 55.39 billion yuan, net profit of 20.62 billion yuan - 2025A: Revenue of 55.19 billion yuan, net profit of 19.15 billion yuan - 2026E: Revenue of 61.09 billion yuan, net profit of 19.27 billion yuan - 2027E: Revenue of 69.76 billion yuan, net profit of 21.30 billion yuan - 2028E: Revenue of 79.88 billion yuan, net profit of 24.16 billion yuan [4][11]. - Profitability Metrics: - Gross margin for 2025 was 80.3%, and adjusted net profit margin was 35.5% [6]. - The company has increased its brand promotion expenses, leading to a slight rise in expense ratios [6][9]. Brand and Product Performance - The company has a diversified product matrix, with "Kefumei" generating revenue of 44.70 billion yuan, down 1.6% year-on-year, while "Keli Jin" achieved a revenue of 9.18 billion yuan, up 9.2% year-on-year [8][9]. - The company has established a strong market presence in medical beauty and is expected to launch new products that will enhance its competitive edge [9]. Market and Channel Strategy - The company is expanding its global presence, having entered 1,700 public hospitals and 3,000 private institutions, as well as over 130,000 chain pharmacies [9]. - The direct sales channel accounted for 74.9% of total revenue, with a slight increase in its proportion [8][9]. Valuation and Future Outlook - The company is expected to see revenue growth of 11% in 2026, 14% in 2027, and 15% in 2028, with corresponding net profit growth of 1%, 11%, and 13% [9]. - The price-to-earnings (P/E) ratio is projected to be 15 for 2026, 14 for 2027, and 12 for 2028, indicating a favorable valuation outlook [4][9].

Investment Rating - The investment rating for the company is "Buy" (maintained) [1] Core Views - The approval of the first type I recombinant collagen for medical aesthetics opens new growth opportunities for the company, with expectations for a performance recovery in 2026 [1] - The company reported a revenue of 55.2 billion yuan in 2025, a slight decrease of 0.4% year-on-year, and a net profit attributable to shareholders of 19.15 billion yuan, down 7.2% year-on-year [8] - The company has adjusted its profit forecasts for 2026-2027 due to increased industry competition and short-term impacts on sales, with net profits expected to be 19.8 billion yuan in 2026 and 22.7 billion yuan in 2027 [1] Financial Performance Summary - Revenue projections for 2024A to 2028E are as follows: 5,539 million yuan (2024A), 5,519 million yuan (2025A), 6,034 million yuan (2026E), 6,917 million yuan (2027E), and 8,292 million yuan (2028E) [1] - Net profit attributable to shareholders is projected to be 2,062 million yuan (2024A), 1,915 million yuan (2025A), 1,978 million yuan (2026E), 2,270 million yuan (2027E), and 2,658 million yuan (2028E) [1] - The company's earnings per share (EPS) is expected to be 1.93 yuan (2024A), 1.79 yuan (2025A), 1.85 yuan (2026E), 2.12 yuan (2027E), and 2.48 yuan (2028E) [1] - The current price-to-earnings (P/E) ratio is 14.10 for 2024A, 15.19 for 2025A, 14.70 for 2026E, 12.81 for 2027E, and 10.94 for 2028E [1]